A carregar...
Antibodies to the cytoplasmic domain of PD-L1 most clearly delineate cell membranes in immunohistochemical staining
Blocking the PD-1 pathway has clinical benefit in metastatic cancer and has led to the approval of the monoclonal antibodies (mAbs) pembrolizumab and nivolumab to treat melanoma and nivolumab for non-small cell lung cancer. Expression of PD-L1 on the cell surface of either tumor cells or infiltratin...
Na minha lista:
| Publicado no: | Cancer Immunol Res |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4743889/ https://ncbi.nlm.nih.gov/pubmed/26546452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0116 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|